The Role of Oral Contraceptive Pills in Hidradenitis Suppurativa: A Cohort Study
MetadataShow full item record
AuthorMontero Vilchez, Trinidad; Valenzuela Amigo, Andrea; Cuenca Barrales, Carlos; Arias Santiago, Salvador Antonio; Leyva García, Ana María; Molina Leyva, Alejandro
ContraceptivesHidradenitis suppurativaPremenstrual syndrome
Montero-Vilchez, T.; Valenzuela-Amigo, A.; Cuenca-Barrales, C.; Arias-Santiago, S.; Leyva-García, A.; Molina-Leyva, A. The Role of Oral Contraceptive Pills in Hidradenitis Suppurativa: A Cohort Study. Life 2021, 11, 697. https://doi.org/10.3390/life11070697
There is a need to establish the role of antiandrogens as an alternative or concomitant therapy for hidradenitis suppurativa (HS). Thus, the objectives of this study are (1) to assess the effectiveness of oral contraceptive pills (OCPs) at week 12 in HS women, and (2) to describe the clinical profile of patients receiving oral contraceptive pills (OCPs). A prospective observational study was designed. This study included 100 participants, 50 women with HS who started OCPs for the first time at our HS Clinic and 50 participants without OCP treatment. The main outcome of interest was the percentage of reduction in total abscess and inflammatory nodule (AN) count at week 12. Thirty-three women received combined OCPs and 17 non-combined OCP. HS patients with OCPs treatment were younger (31.7 vs. 40.9 years, p < 0.001), thinner (28.62 vs. 33.35 kg/m2 ), and have a higher number of areas affected (2.32 vs. 1.38, p = 0.02) than those without OCPs. After 12-weeks of treatment, it was observed that the percentage of AN reduction was higher in HS women receiving OCP than in patients without OCP (53.9% vs. 38.42%, p = 0.049). It was observed that OCP prescription (β = 3.79, p = 0.034) and concomitant therapy (β = 3.91, p = 0.037) were independently associated with a higher % AN when controlling for disease duration, concomitant therapy, and treatment with/without OCP (Rˆ2 = 0.67). The factors potentially associated with the percentage AN reduction at week 12 in HS women treated with OCPs were disease duration (β = −1.327, p = 0.052), concomitant therapy (β = 11.04, p = 0.079), and HS worsening with the menstrual cycle (β = 10.55, p = 0.087). In conclusion, OCPs might be effective for improving AN count in women with HS. Women whose HS worsens in relation to the menstrual cycle and have a shorter disease may benefit more from the therapeutic effect of OCPs.